waldenstrom's macroglobulinemia Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (2)

Phase 2 (2)

Interventional (2)

Dana-Farber Cancer Institute (1)
Institute of Hematology & Blood Diseases Hospital (1)

No (2)

No (2)

Adult (18+) (2)

I am/have/had

I am/have/hadwaldenstrom's macroglobulinemia

I am/have/hadlymphoma

I am/have/hadmeasurable disease

I am/have/hadcancer

I am/have/hadneutrophil count

I am/have/hadabsolute neutrophil count

I am/have/hadneuropathy

I am/have/hadamyloidosis

I am/have/hadnight sweats

I am/have/hadcryoglobulinemia

I am/have/hadigm level

I am/have/hadfever

I am/have/hadcytopenia

I am/have/hadremission

I am/have/hadindolent lymphoma

I am/have/hadplasmapheresis

I am/have/hadcold agglutinin

I am/have/hadplatelet transfusion

I am/have/hadbone marrow biopsy

I am/have/hadtreatment regimen

added new label for I am/have/had

more

I am looking for

I am looking forfludarabine

I am looking foribrutinib

I am looking forcyclophosphamide

I am looking fordexamethasone

I am looking forgrowth factor

I am looking forixazomib

I am looking forchlorambucil

I am looking forzanubrutinib

I am looking forvenetoclax

added new label for I am looking for

more

Advanced Filters

Loading...

Found 2 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 2
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Oncology
Recruiting

Zanubrutinib Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

This study aims to evaluate the efficacy of BTK inhibitor Zanubrutinib combined with Ixazomib and Dexamethasone (ZID) for the newly diagnosed Waldenstrom Macroglobulinemia. This ZID regimen will be given up to 24 months and stopped for observation. We propose this combination will improve the deep remission (VGPR) compared to single …

lymphoma

dexamethasone

cytopenia

cold agglutinin

fludarabine

0 views
19 Feb, 2024

Phase 2
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Hematology
Recruiting

Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies.

measurable disease

venetoclax

ibrutinib

neutrophil count

serum pregnancy test

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.